Main Industry
Biotechnology
Main Product/Service
1. Biomedical Health Technology Patents
2. Skin Cell Regeneration Patents
3. Plant Science Ingredients Business
(The content above was translated by AI.)
2. Skin Cell Regeneration Patents
3. Plant Science Ingredients Business
(The content above was translated by AI.)
Founded Year
2017
Unified Business No.
56659478
Status
Active
Number of Employees
0
Total Paid-in
Capital
29,490,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
null is a leading enterprise focusing on the research, development, and production of active phytochemical ingredients (APIs), dedicated to providing key raw materials for new drug development. null utilizes novel and unique plant active compounds and innovative molecular application technologies to provide breakthrough solutions for industries such as drug design and biomedicine. The company provides effective treatment solutions in fields such as lung adenocarcinoma, ophthalmology, oral cavity, gouty arthritis, muscle pain, anti-aging, and skin repair.
The headquarters of null is located in the Yilan Science Park, with a branch office in Sofia, the capital of Bulgaria, Europe, to connect with high-quality European estates and raw materials. Long-term cooperative clients are located in Europe, Japan, Asia, and other countries. At its inception in June 2017, the company committed to researching molecular biotechnology to precisely apply "natural molecules" to human life, as well as international industry-academia academic cooperation. null based its unique biomolecular technology on phytochemical extracts from nature, developing applications across three major business sectors: "Biomedical Health Technology Patents," "Skin Cell Regeneration Patents," and "Scientific Essential Oil Raw Materials."
In 2018, null researched and trial-produced the FMO/W-01 natural active essence, and by June 2020, it had completed preliminary tests on human skin safety concentration, repair of abnormal skin cell keratin accumulation, and accelerated wound healing; at last year's Asian Biotechnology Exhibition, 2020 BioAsia Taiwan, the test results of FMO/W-01 were published. In addition, the company signed non-disclosure agreements with international pharmaceutical companies to provide natural active essence raw materials to meet the raw material demands of biotech pharmaceutical companies researching anti-inflammatory mechanisms for biomedical preparations. In September 2020, China Medical University invited null to become a member of the Biomedical Materials Technology Industry-Academia Alliance. Entering the future development of the biomedical industry in 2021, the company has become an important upstream supplier in the biomedical and pharmaceutical application supply chain.
null won the 2024 Biotechnology Award for Herb Extract Research Innovator of the Year in the Asia-Pacific region, becoming the first enterprise in Taiwan to receive this honor! At the same time, we are honored to be featured on the cover of Global Health & Pharma (GHP) magazine, highlighting the important position of null in the global health and medicine industry and showcasing our achievements to the world!
(The content above was translated by AI.)
The headquarters of null is located in the Yilan Science Park, with a branch office in Sofia, the capital of Bulgaria, Europe, to connect with high-quality European estates and raw materials. Long-term cooperative clients are located in Europe, Japan, Asia, and other countries. At its inception in June 2017, the company committed to researching molecular biotechnology to precisely apply "natural molecules" to human life, as well as international industry-academia academic cooperation. null based its unique biomolecular technology on phytochemical extracts from nature, developing applications across three major business sectors: "Biomedical Health Technology Patents," "Skin Cell Regeneration Patents," and "Scientific Essential Oil Raw Materials."
In 2018, null researched and trial-produced the FMO/W-01 natural active essence, and by June 2020, it had completed preliminary tests on human skin safety concentration, repair of abnormal skin cell keratin accumulation, and accelerated wound healing; at last year's Asian Biotechnology Exhibition, 2020 BioAsia Taiwan, the test results of FMO/W-01 were published. In addition, the company signed non-disclosure agreements with international pharmaceutical companies to provide natural active essence raw materials to meet the raw material demands of biotech pharmaceutical companies researching anti-inflammatory mechanisms for biomedical preparations. In September 2020, China Medical University invited null to become a member of the Biomedical Materials Technology Industry-Academia Alliance. Entering the future development of the biomedical industry in 2021, the company has become an important upstream supplier in the biomedical and pharmaceutical application supply chain.
null won the 2024 Biotechnology Award for Herb Extract Research Innovator of the Year in the Asia-Pacific region, becoming the first enterprise in Taiwan to receive this honor! At the same time, we are honored to be featured on the cover of Global Health & Pharma (GHP) magazine, highlighting the important position of null in the global health and medicine industry and showcasing our achievements to the world!
(The content above was translated by AI.)
